A machine-learning model developed by UC Davis Health clinicians and data scientists can accurately predict the risk of developing hepatocellular carcinoma (HCC) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The model, which was validated on a large dataset, identified four additional risk factors a...
Recent US nationwide data reveal rising HCC incidence and mortality rates primarily affecting men and older adults. The study highlights disparities among racial/ethnic groups and underscores the need for targeted early detection, intervention, and treatment strategies to improve patient outcomes.
A study by UC Davis Health found that a single dose of BCG reduced liver tumor burden and extended the survival of mice with liver cancer. The vaccine boosted the body's immunity, leading to tumor shrinkage and improved liver function.
A research team has identified an immune biomarker that explains why some patients with hepatocellular carcinoma (HCC) fail to respond to immunotherapy. The biomarker could lead to the development of new immunotherapies by restoring an effective immune response against HCC.
Researchers identified blood proteomic markers associated with hepatocellular carcinoma (HCC) in patients with cirrhosis. The study found a set of biomarkers, including TGF-β driven mechanistic biomarkers and Myostatin and Pyruvate Kinase M2, which may stratify risk for HCC.
Korea University researchers found that perioperative radiotherapy significantly improves survival rates among HCC patients at high risk of recurrence. The study suggests that radiotherapy can reduce recurrence and improve survival in these patients, providing a significant adjuvant treatment option.
A recent study discovered a causal link between oncofoetal ecosystems and liver cancer recurrence, highlighting their potential as biomarkers for treating hepatocellular carcinoma (HCC). The research found that oncofoetal reprogramming contributes to EMT, tumour cell proliferation, and response to immunotherapy.
Recent advancements in AI, particularly deep learning and neural networks, offer significant potential for improving HCC diagnosis. Early detection of HCC is crucial, as curative treatments like surgery and liver transplant are only possible in the early stages.
This review highlights the role of single-cell sequencing in HBV-HCC research, shedding light on tumor heterogeneity and immune microenvironment dynamics. The study provides new avenues for visualizing intratumoral and intertumoral heterogeneity, monitoring tumor progression, and preventing cellular deterioration.
Researchers at UC Davis Comprehensive Cancer Center have shown that inhibiting galectin 1 protein using gene therapy can shrink liver cancer in mice, improving the anti-cancer immune response and increasing killer T cells. This approach has potential as a treatment for HCC prevention.
Scientists have developed a drug-eluting hydrogel that provides sustained, pH-dependent drug co-delivery and promotes anti-tumor immune responses, reducing tumor cell proliferation and growth. The treatment shows promise in treating hepatocellular carcinoma, with enhanced efficacy compared to traditional methods.
A new study has found that different gross subtypes of hepatocellular carcinoma (HCC) have significantly different prognoses and molecular characteristics. The study suggests that gross classification may be valuable for developing individualized diagnosis and treatment strategies for HCC, with potential implications for patient outcomes.
US-born Latinos have a higher incidence of liver cancer than foreign-born Latinos, suggesting lifestyle and cultural differences may contribute to the trend. Researchers found second and third generation Mexican Americans had a 37% and 66% higher risk of liver cancer, respectively.
A clinical trial shows that a combination of atezolizumab and bevacizumab can reduce cancer recurrence in liver cancer patients by one-third after curative-intent resection or ablation. The therapy has improved recurrence-free survival rates compared to active surveillance, offering new hope for these patients.
Researchers from Columbia University have validated GLS2's ability to promote ferroptosis in murine models. This study suggests that targeting GLS2 may be a potential therapeutic strategy against liver diseases, particularly hepatocellular carcinoma.
A study published in the Chinese Medical Journal reveals that methotrexate can be an effective treatment for liver cancer with a specific genetic mutation. The drug works by disrupting nucleotide synthesis in cancer cells, making it a promising alternative to current first-line treatments.
A new gene therapy study has identified microRNA-22 as a potential treatment for liver cancer, achieving better survival outcomes and reducing inflammation compared to the current FDA-approved drug lenvatinib. The treatment was administered via a single intravenous injection and showed no observable toxicity.
A personalized calculator helps clinicians estimate risk reduction from adjuvant TACE in HCC patients. The model identifies high-risk patients who may benefit from this treatment to prevent early recurrence.
Researchers used base editors to introduce specific combinations of activating and inactivating mutations into healthy organoids, creating realistic models for various types of cancer. This allows for further investigation into the development and treatment of cancer, with potential applications including testing new drugs.
Researchers developed new methods for detecting drug-induced hepatotoxicity using 3D cell cultures and mass spectrometry imaging, identifying biomarkers and effective interventions. A zeolite-based protein corona method was also used to characterize plasma proteins, enabling the identification of low-abundance proteins and their potent...
A study published in Cancer Research identifies a novel mechanism by which liver cancer develops, involving the aberrant activation of the Wnt signaling pathway and the gene GREB1. The research reveals that GREB1 is responsible for integrating conflicting cellular states of differentiation and proliferation, leading to tumor promotion.
Researchers identified three immune cell types within tumor niches that determine which patients respond positively to checkpoint blockade immunotherapy. The study may inform new approaches to cancer treatment.
A new study found that obesity is associated with an increased risk of certain cancers, with stronger links in female patients for gallbladder and endometrial cancer. The study also revealed differential effects between sexes on colorectal, esophageal, and liver cancer.
A new study from the USC Norris Comprehensive Cancer Center found that immigrant adults with liver cancer have a significantly higher five-year survival rate compared to those born in the US. The study identified disparities in survival rates across different racial and ethnic groups, with immigrants demonstrating better outcomes.
Researchers identified high expression of glypican-1 in primary solid tumors, correlating with poor prognosis in various cancer types. Suppression of GPC1 attenuated cancer cell proliferation, suggesting its potential as a novel diagnostic tool and target for therapy.
Researchers at City University of Hong Kong identified lysyl hydroxylase 1 (LH1) as a key factor in promoting confined migration of liver and pancreatic cancer cells. The study found that LH1 promotes metastasis by stabilizing Septin2, which enhances the actin network.
Researchers found a molecular staple called NIHCOLE that helps liver cancer cells repair broken DNA, making them resistant to radiotherapy. Understanding this mechanism may lead to the development of new strategies to combat liver cancers with poor prognosis.
Researchers successfully applied AlphaFold AI to an end-to-end platform, discovering a novel target and developing a potent hit molecule for liver cancer. The study demonstrates the potential of AI-powered drug discovery to accelerate treatment development.
Researchers from prominent institutions discuss hepatocellular carcinoma's pathogenesis, genomic heterogeneity, and targeted therapy options. The review aims to characterize HCC's complexities and develop clinically relevant biomarkers for better management.
Researchers at USC Keck School of Medicine found that liver cancer cells hijack circadian clock proteins to replicate and spread. Inhibiting these proteins can prevent cancer cell multiplication and potentially improve outcomes for patients with liver cancer.
Researchers found that plasma GH levels are a potential biomarker for predicting treatment outcomes in patients with advanced HCC treated with Atezo/Bev. The study showed significantly superior overall survival and non-significant trend in favor of GH-low patients compared to GH-high patients.
Researchers at HKUMed identify Δ42PD-1 as a key player in suppressing killer T cells and promoting tumor growth in HCC. Targeting this protein with an antibody can inhibit tumor growth and increase functional killer T cells, offering new hope for immunotherapy against HCC
Researchers found that dietary saturated/trans fats, but not cholesterol, can trigger hepatic angiogenesis and lymphangiogenesis in mice, leading to the promotion of hepatic tumors. This process is driven by the JNK-HIF1α-VEGF-C axis.
Researchers found that P2-HNF4α expression is associated with p-STAT3 and c-Myc expression in NAFLD patients, suggesting potential biomarkers for hepatocellular carcinoma (HCC) risk. Additionally, p-STAT3 expression was linked to hypertension, while c-Myc expression was associated with advanced fibrosis.
Researchers discovered three essential amino acids - leucine, valine, and tryptophan - as potential metabolic biomarkers for HCC. The study used metabolomics to analyze the differences in tumor and non-tumor tissue metabolomes, revealing striking differences that could aid in diagnosis.
A new study published in JAMA Surgery compares robotic liver resection with open liver resection for treating hepatocellular carcinoma. Robotic liver resection is found to be a safe treatment option for patients with compromised liver function, achieving comparable oncologic efficacy to traditional open surgery.
A new AI-powered blood test, DELFI, has been developed to detect liver cancer with high accuracy. The test detected over 80% of liver cancers in a study of 724 individuals, with an overall sensitivity of 88% and specificity of 98%.
Researchers evaluated modified CEUS using perfluorobutane for diagnosing hepatocellular carcinoma in high-risk patients. The study found no significant difference in sensitivity, specificity, or accuracy between modified CEUS and CT/MRI LI-RADS v2018.
Researchers at VCU Massey Cancer Center have found strong evidence for testing a novel drug in liver cancer treatment. MDA-9 inhibition may be an effective approach for hepatocellular carcinoma (HCC), with potential synergies with other therapeutics.
A randomized phase III trial shows that adding radiation therapy to systemic therapy can delay tumor progression and lengthen survival without compromising quality of life. The combination of SBRT and sorafenib appears more effective than the drug on its own.
Adding stereotactic body radiation therapy (SBRT) to sorafenib significantly improves overall survival, progression-free survival, and time to tumor progression in patients with advanced hepatocellular carcinoma. SBRT was shown to be effective without increasing toxicity.
Researchers have discovered that reduced TGFBR2 abundance is significantly associated with hepatocellular carcinoma (HCC) in patients with cirrhosis. An AI-based process accurately identified HCC tissue, confirming the biomarker's potential for early detection.
A proof-of-concept study developed three machine learning models to predict posttreatment recurrence in early-stage hepatocellular carcinoma patients. The models achieved high accuracy using imaging data alone, while combining clinical data did not significantly improve performance.
Researchers from Keck School of Medicine found a strong association between PFOS exposure and liver cancer risk, with the strongest link seen in the top 10% of PFOS exposure. The study suggests that PFOS may disrupt normal liver function, leading to non-alcoholic fatty liver disease and increased risk of liver cancer.
Researchers developed a new technology that can detect early-stage hepatocellular carcinoma using nanoparticles, which are released by tumor cells and can be detected in circulation. The technology, called HCC EV SPA, has the potential to enable rapid and affordable detection of the disease, leading to improved survival rates.
Researchers discovered that liver cancer cells modify their metabolism to leave them susceptible to disruptions in arginine supply, a key molecule. A three-pronged approach targeting tumor metabolism, blocking survival-promoting responses, and starving tumors of arginine can induce senescence, making cancer cells killable.
A new study published in the Journal of the American College of Surgeons suggests that liver transplantation is a viable option for older patients with liver cancer, offering a significant survival benefit. The research compares outcomes between patients over 70 who received liver transplants and those who underwent ablative treatments...
Researchers at Cedars-Sinai Cancer have identified a novel immune checkpoint pathway that could lead to better understanding and treatment of hepatocellular carcinoma. The study suggests that blocking this pathway, combined with immunotherapy, may provide a new therapeutic strategy for liver cancer.
A new review analyzes the efficacy of current non-invasive methods for assessing non-alcoholic fatty liver disease (NAFLD) and associated conditions. Blood-based biomarker tests and imaging methods are explored, with some showing promise in early diagnosis and staging liver disorders.
Researchers identified two novel biomarkers that predict response to immunotherapy and adverse events in liver cancer patients. The study's findings enable more effective and individualized treatment of primary liver cancer hepatocellular carcinoma (HCC) patients, with fewer side effects.
A new tsRNA, tRF-Gln-TTG-006, has been identified in the serum of liver cancer patients as a promising biomarker for early diagnosis and prognosis. This discovery provides valuable information on the relationship between tsRNAs and liver cancer development.
Researchers found that sequencing drug combinations can enhance the anti-tumor immune response in liver cancer, potentially reducing toxic drug exposure. The new strategy primes the tumor with an immune checkpoint inhibitor before using a multikinase inhibitor, enhancing its effectiveness.
The American Gastroenterological Association (AGA) has issued new clinical practice guidelines on systemic therapy for HCC, emphasizing the importance of consulting a multidisciplinary team of healthcare professionals. The guidelines provide specific patient scenarios and treatment options to help hepatologists make informed decisions.
Codiak BioSciences' exoASO-STAT6 demonstrates potent anti-tumor efficacy by reprogramming tumor-associated macrophages to an M1 phenotype, showing promise as a monotherapy candidate for hepatocellular carcinomas and other cancers. The company plans to initiate Phase 1 clinical trials in the first half of 2022.
A team of researchers has reprogrammed the tumor microenvironment of liver cancer by using mRNA nanoparticles, restoring the function of the p53 master regulator gene. The approach increased antitumor immune responses in hepatocellular carcinoma laboratory models and shows promise for treating HCC and other cancers.
A new Chinese Medical Journal study explores the risks of non-alcoholic steatohepatitis (NASH) turning into liver cancer. Early detection through simple medication and lifestyle changes can prevent NAFLD from progressing to more severe conditions, such as cirrhosis and hepatocellular carcinoma.
The American Society for Radiation Oncology (ASTRO) has released a new clinical guideline outlining the use of external beam radiation therapy (EBRT) to treat adult patients with primary liver cancers. The guidelines emphasize multidisciplinary care and provide evidence-based recommendations on indications, dosing, techniques, and trea...
Researchers have described a dynamic genomic landscape of tumour heterogeneity in hepatocellular carcinoma, highlighting the need for novel strategies targeting heterogeneous tumors. The study, published in National Science Review, used multi-omic data to reveal variations in genetic and transcriptomic profiles across patients.
Researchers have developed a CRISPR/Cas9 gene editing system to enhance the effectiveness of sonodynamic therapy, allowing tumors to be effectively shrunk in a mouse model of liver cancer. The technology reduces antioxidant defense systems, increasing cancer cell death from the treatment.
New study suggests inhibiting Shp2 in tumor cells may boost tumor growth and survival, complicating its use as a potential cancer therapy for HCC.